Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes industry. Recently, Tesla (TSLA) CEO Elon Musk added to the buzz by sharing his views on weight-loss-focused pharmaceutical companies. In a widely discussed X post, Musk revealed his preference for Eli Lilly’s (LLY) Mounjaro over Novo Nordisk’s (NVO) Ozempic. Musk’s casual comments and his own weight loss have sparked curiosity around these GLP-1 drugs, which are revolutionizing diabetes care and reshaping the weight-loss market.
Eli Lilly and Novo Nordisk both have been making significant breakthroughs in the pharmaceutical realm and have a strong history of delivering value to shareholders. However, which stock is the better long-term growth play? Let’s take a closer look to find out.
